Early biochemical outcomes following permanent interstitial brachytherapy as monotherapy in 1050 patients with clinical T1–T2 prostate cancer
- 31 July 2006
- journal article
- Published by Elsevier BV in Radiotherapy and Oncology
- Vol. 80 (1), 57-61
- https://doi.org/10.1016/j.radonc.2006.06.004
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- The impact of hormone therapy on post-implant dosimetry and outcome following Iodine-125 implant monotherapy for localised prostate cancerRadiotherapy and Oncology, 2005
- Results of permanent prostate brachytherapy, 13 years of experience at a single institutionRadiotherapy and Oncology, 2004
- Relative influence of Gleason score and pretreatment PSA in predicting survival following brachytherapy for prostate cancerBrachytherapy, 2003
- The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinomaRadiotherapy and Oncology, 2000
- Palladium-103 brachytherapy for prostate carcinomaInternational Journal of Radiation Oncology*Biology*Physics, 2000
- Post-treatment PSA ≤0.2 ng/ml defines disease freedom after radiotherapy for prostate cancer using modern techniquesUrology, 1999
- Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable diseaseUrology, 1999
- CANCER RECURRENCE AND SURVIVAL RATES AFTER ANATOMIC RADICAL RETROPUBIC PROSTATECTOMY FOR PROSTATE CANCERJournal of Urology, 1998
- Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and GoserelinNew England Journal of Medicine, 1997
- Consensus statement: Guidelines for PSA following radiation therapy1International Journal of Radiation Oncology*Biology*Physics, 1997